LakeShore Biopharma (LSB) announced that the independent special committee of the Company’s board of directors, formed to evaluate and consider the previously announced revised preliminary non-binding proposal letter dated August 26, has retained Kroll, as its financial advisor, Gibson, Dunn & Crutcher as its U.S. legal counsel, and Maples and Calder as its Cayman Islands legal counsel. The Special Committee is continuing its review and evaluation of the Proposal. The Board cautions the Company’s shareholders and others considering trading the Company’s securities that no decisions have been made with respect to the Proposal.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LSB:
- LakeShore Biopharma Receives Revised Acquisition Proposal from Consortium
- LakeShore Biopharma receives non-binding acquisition proposal
- LakeShore Biopharma Receives Acquisition Proposal from Oceanpine Capital
- LakeShore Biopharma receives non-binding acquisition proposal from Oceanpine
- LakeShore Biopharma Reports FY2025 Financial Results with Improved Profitability